INSPIRE trial
Jump to navigation
Jump to search
Introduction
International randomized trial toptropium compared with salmeterol/fluticasone (Advair) supported by the manufacturer of Advair
1323 patients with severe COPD, 2 year study
inhaled salmeterol/fluticasone 50/500 ug BID vs
inhaled tiotropium 18 ug QD + inhaled placebo QD
Primary endpoint:
- exacerbations that required antibiotics, systemic steroids or hospitalization
Results:
- more patients in the tiopropium group withdrew
- primary endpoint similar in both groups
- questionnaires about health & well-being slightly better in salmeterol/fluticasone group
- higher rate of pneumonia in salmeterol/fluticasone group 8% vs 4 %
- mortality lower in salmeterol/fluticasone group 3% vs 6%
More general terms
References
- ↑ Wedzicha JA et al, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17916806